0855 ET - Stifel says CoreWeave's acquisition of Core Scientific could bolster CoreWeave's ability to scale, free up around $10 billion in lease liability commitments and about $5 billion in committed capex, among other benefits, but the analysts remain cautious short-term. "While we are positive on the longer-term benefits from the acquisition, we think there are key near-term overhangs for CoreWeave to pass," say the analysts, who downgrade CoreWeave to hold but raise the price target to $115 from $75. CoreWeave is down 1.3% premarket. (denny.jacob@wsj.com; @pennedbyden)

(END) Dow Jones Newswires

July 08, 2025 08:55 ET (12:55 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.